


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31200018</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1878-0849</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jun</Month>
                        <Day>11</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of medical genetics</Title>
                <ISOAbbreviation>Eur J Med Genet</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Fabry disease caused by the GLA p.Phe113Leu (p.F113L) variant: Natural history in males.</ArticleTitle>
            <Pagination>
                <MedlinePgn>103703</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S1769-7212(19)30198-3</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejmg.2019.103703</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">aims and methods. The α-galactosidase gene (GLA) c.337T&gt;C/p.Phe113Leu variant was originally described in patients with late-onset cardiac forms of Fabry disease (FD), who had residual α-galactosidase activity. It has since emerged as the most commonly reported GLA variant in Portuguese subjects diagnosed with FD but is also prevalent in the Italian population, where two boys carrying the GLA Leu113 allele were identified in a large-scale newborn screening program, the variant allele segregating in both cases with the same surrounding haplotype. To further delineate the genotype-phenotype correlations of this GLA variant, we have reviewed the natural history and clinical phenotypes of 11 symptomatic Portuguese males, from 10 unrelated families originating from several different areas in mainland Portugal and Madeira Island, who were diagnosed with FD associated with the GLA Leu113 allele in a diversity of clinical and screening settings. Nine of the patients were the probands of their respective families. To test whether the GLA Leu113 allele inherited by the 10 Portuguese and the two Italian families resulted from independent mutational events, we have additionally performed a haplotype analysis with 5 highly polymorphic, closely linked microsatellite markers surrounding the GLA gene.</AbstractText>
                <AbstractText Label="RESULTS AND CONCLUSIONS" NlmCategory="CONCLUSIONS">Hemizygosity for the GLA Leu113 variant allele is associated with a late-onset form of FD, invariably presenting with severe cardiac involvement. Clinically relevant cerebrovascular and kidney involvement may also occur in some patients but the pathogenic relationship between the incomplete α-galactosidase deficiency and the risks of stroke and of chronic kidney disease is not straightforward. The observation that the Leu113 allele segregated within the same GLA microsatellite haplotype in both the Portuguese and Italian families suggests its inheritance from a common ancestor.</AbstractText>
                <CopyrightInformation>Copyright © 2019. Published by Elsevier Masson SAS.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Oliveira</LastName>
                    <ForeName>João P</ForeName>
                    <Initials>JP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Service of Medical Genetics, São João University Hospital Center, 4200-319, Porto, Portugal; Unit of Genetics, Department of Pathology, Faculty of Medicine, University of Porto, 4200-319, Porto, Portugal; Institute for Research and Innovation in Health [Instituto de Investigação e Inovação em Saúde] - I3S, University of Porto, 4150-180, Porto, Portugal. Electronic address: jpo@med.up.pt.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nowak</LastName>
                    <ForeName>Albina</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Endocrinology and Clinical Nutrition, University of Zurich, 8091, Zürich, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barbey</LastName>
                    <ForeName>Frédéric</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Genetic Medicine, Lausanne University Hospital, Lausanne, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Torres</LastName>
                    <ForeName>Márcia</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Service of Cardiology, Hospital of Santo Tirso, 4780-371, Santo Tirso, Portugal.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nunes</LastName>
                    <ForeName>José P</ForeName>
                    <Initials>JP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Service of Cardiology, São João University Hospital Center, 4200-319, Porto, Portugal.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teixeira-E-Costa</LastName>
                    <ForeName>Fernando</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Service of Nephrology, Garcia de Orta Hospital, 2805-267, Almada, Portugal.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carvalho</LastName>
                    <ForeName>Fernanda</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Unit of Renal Pathology, Service of Nephrology, Curry Cabral Hospital, 1069-166, Lisbon, Portugal.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sampaio</LastName>
                    <ForeName>Susana</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Service of Nephrology, São João University Hospital Center, 4200-319, Porto, Portugal.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tavares</LastName>
                    <ForeName>Isabel</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Service of Nephrology, São João University Hospital Center, 4200-319, Porto, Portugal; Uninefro, Santo Tirso Hemodialysis Clinic, 4780-383, Santo Tirso, Portugal.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pereira</LastName>
                    <ForeName>Odete</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Service of Nephrology, São João University Hospital Center, 4200-319, Porto, Portugal.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Soares</LastName>
                    <ForeName>Ana L</ForeName>
                    <Initials>AL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vil'Alva Family Health Center, 4780-484, Santo Tirso, Portugal.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carmona</LastName>
                    <ForeName>Cátia</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Service of Neurology, Garcia de Orta Hospital, 2805-267, Almada, Portugal.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cardoso</LastName>
                    <ForeName>Maria-Teresa</ForeName>
                    <Initials>MT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinic for Adult Metabolic Diseases, Inherited Metabolic Diseases Reference Center, São João University Hospital Center, 4200-319, Porto, Portugal.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jurca-Simina</LastName>
                    <ForeName>Iulia E</ForeName>
                    <Initials>IE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Genetics, University of Versailles / Paris-Saclay University, 78180, Montigny, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spada</LastName>
                    <ForeName>Marco</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinic for Metabolic Diseases, Department of Pediatric Sciences, Regina Margherita Hospital, 10126, Turin, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferreira</LastName>
                    <ForeName>Susana</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Unit of Genetics, Department of Pathology, Faculty of Medicine, University of Porto, 4200-319, Porto, Portugal; Institute for Research and Innovation in Health [Instituto de Investigação e Inovação em Saúde] - I3S, University of Porto, 4150-180, Porto, Portugal.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Germain</LastName>
                    <ForeName>Dominique P</ForeName>
                    <Initials>DP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Genetics, University of Versailles / Paris-Saclay University, 78180, Montigny, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Eur J Med Genet</MedlineTA>
            <NlmUniqueID>101247089</NlmUniqueID>
            <ISSNLinking>1769-7212</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Alpha-galactosidase gene (GLA)</Keyword>
            <Keyword MajorTopicYN="N">Fabry disease</Keyword>
            <Keyword MajorTopicYN="N">Haplotype</Keyword>
            <Keyword MajorTopicYN="N">Microsatellite markers</Keyword>
            <Keyword MajorTopicYN="N">p.Phe113Leu (p.F113L) pathogenic variant</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31200018</ArticleId>
            <ArticleId IdType="pii">S1769-7212(19)30198-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ejmg.2019.103703</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

